NICE 'no' for short bowel syndrome drug Revestive

13 November 2017

UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has published draft guidance today that does not recommend Revestive (teduglutide) for treatment of people with short bowel syndrome (SBS).

The drug, from Ireland-headquartered Shire (LSE: SHP), is licensed for treating patients in a stable condition after their intestine has adapted post-surgery. SBS is a chronic condition relating to a reduced ability to absorb nutrients in the intestine.

Shire’s shares dipped 0.75% to 3,508 pence by mid-afternoon. Shire gained rights to Gattex/Revestive, as well as Natpara/Natpar (rhPTH [1-84]) for the treatment of hypoparathyroidism (HPT), when it acquired US firm NPS Pharmaceuticals in 2015 for a total consideration of around $5.2 billion. Gattex/Revestive (teduglutide) generated sales of $219 million in 2016, a year-on-year rise of 55%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK